Table 1.
Baseline characteristics.
| Variable | UC | CD |
|---|---|---|
| Patients, No. (%) | 73 (35%) | 137 (65%) |
| Age (years) | 42 (19–69) | 37 (17–78) |
| Male sex, No. (%) | 49 (67%) | 72 (53%) |
| Time since diagnosis (years) | 9 (1–36) | 12 (0–39) |
| Duration of treatment (months) | 30 (1–98) | 46 (1–64) |
| CRP (mg/liter) | 4 (1–46) | 5 (1–45) |
| F-calprotectin (mg/kg) | 167 (20–1250) | 147 (20–1250) |
| PMS/HBI | 1 (0–9) | 3 (0–11) |
| Disease distribution, No. (%) | ||
| Rectum | 6 (8%) | |
| Left-sided colon | 27 (37%) | |
| Extensive/total colon | 40 (55%) | |
| Upper GI | 3 (2%) | |
| Ileum | 54 (39%) | |
| Colon | 26 (19%) | |
| Ileocolon | 54 (40%) | |
| Perianal | 17 (12.4%) | |
| Anti-TNFα agent, No. (%) | ||
| Adalimumab | 24 (33%) | 103 (75%) |
| Infliximab | 49 (67%) | 34 (25%) |
| Prev. biol. exp., No. (%) | 16 (21.9%) | 54 (39.4%) |
| SDC 6 months prior to incl., No. (%) | 15 (20.5%) | 26 (19%) |
| Nonstandard (high) dosing, No. (%) | ||
| Adalimumab | 2 (8.3%) | 11 (10.9%) |
| Infliximab | 30 (61.2%) | 20 (58.8%) |
| Medication, No. (%) | ||
| 5-ASA | 57 (78%) | 5 (4%) |
| Corticosteroids | 8 (11%) | 4 (3%) |
| Antibiotics | 5 (7%) | 2 (2%) |
| Immunomodulators | 6 (8%) | 17 (12%) |
Values are absolute numbers or medians (ranges).
5-ASA, 5-aminosalicylic acid; CRP; C-reactive protein; GI, gastrointestinal; HBI, Harvey Bradshaw Index; PMS, Partial Mayo Score; SDC, serum drug concentration; TNF, tumor necrosis factor.